share_log

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022

Bioasis宣布提交截至2022年11月30日的季度财务报表和MD&A
GlobeNewswire ·  2023/01/20 06:10

NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, today announced that it has filed its unaudited quarterly financial statements and management's discussion and analysis for the period ended November 30, 2022. All are available under the Company's profile on SEDAR and on the Company's website at .

康涅狄格州纽黑文,2023年1月19日(Global Newswire)--BiOasis Technologies Inc.(OTCQB:BIOAF;TSX.V:BTI)(The“公司“或”生物绿洲“),一家多资产的罕见和孤儿疾病生物制药公司,开发基于表皮生长因子和差异化的专有xB的临床阶段计划3跨越血脑屏障提供治疗药物的™平台(“BBB“)和治疗中枢神经系统(”氯化萘“)在高度未得到满足的医疗需求领域的疾病,今天宣布,它已经提交了截至2022年11月30日期间的未经审计的季度财务报表和管理层的讨论和分析。所有这些都可以在SEDAR上的公司简介中获得,也可以在公司网站上获得。

On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board

代表BiOasis Technologies Inc.董事会。
Deborah Rathjen,博士,董事会执行主席

Follow on:
Facebook
Instagram
LinkedIn
Twitter

后续内容:
Facebook
Instagram
LinkedIn
推特

BTI-FIN

BTI-FIN

About Bioasis

关于BiOASIS

Bioasis is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit .

BiOASIS是一家多资产罕见和孤儿疾病生物制药公司,开发基于表皮生长因子和xB的临床分期计划3 ™Platform是一项专利技术,用于通过血脑屏障提供治疗药物,并在高度未得到满足的医疗需求领域治疗中枢神经系统疾病。跨越血脑屏障的治疗药物代表着治疗神经疾病的最后前沿。BiOASIS的内部开发计划旨在为与大脑相关的疾病和障碍开发对症和疾病修改治疗。欲了解更多有关该公司的信息,请访问。

Forward Looking Statements

前瞻性陈述

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

本新闻稿中的某些陈述包含1995年《私人证券诉讼改革法》所指的前瞻性陈述,或根据适用的加拿大证券法可能不以历史事实为基础的前瞻性信息,以及包含“相信”、“可能”、“计划”、“将”、“估计”、“继续”、“预期”、“打算”、“预期”和类似表达的其他陈述。此类前瞻性声明或信息涉及已知和未知的风险、不确定性和其他因素,这些风险、不确定性和其他因素可能导致我们的实际结果、事件或发展或行业结果与此类前瞻性声明或信息明示或暗示的任何未来结果、事件或发展大不相同。这些因素包括但不限于我们的开发阶段、缺乏任何产品收入、额外的资本要求、与完成临床试验和获得监管机构批准以销售我们的产品相关的风险、保护我们知识产权的能力、对合作伙伴的依赖、谈判更多公司合作或许可安排的前景及其时机。具体地说,可能导致此类前瞻性声明和信息明示或暗示的实际事件或结果与此类声明和信息明示或暗示的任何未来事件或结果大不相同的某些风险和不确定性包括但不限于:我们开发的产品可能在临床前或临床试验中不成功。, 这些因素包括:我们可能无法实现预期的目标;我们未来的经营业绩不确定,可能会波动;我们可能无法筹集更多资本;我们可能无法成功建立更多的公司合作或许可安排;我们可能无法建立营销活动,推出产品的成本可能高于预期;我们没有商业制造经验;我们可能面临与知识产权相关的未知风险;我们面临来自制药和生物技术公司日益激烈的竞争;以及在提交给加拿大证券监管机构的文件中详细描述的其他因素。鉴于这些风险和不确定性,谨告诫您不要过度依赖此类前瞻性陈述和信息,这些陈述和信息完全受本警告性声明的限制。本文中的所有前瞻性陈述和信息都是基于我们目前的预期,我们没有义务修改或更新此类前瞻性陈述和信息,以反映后续事件或情况,除非法律要求。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任

Contacts:

联系人:

Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082

黛博拉·拉特金博士,董事会执行主席兼首席执行官
邮箱:deborah@biasis.us
203-533-7082

Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989

投资者联系方式:
格雷姆·迪克
科尔韦尔资本公司
邮箱:graeme@colwell capal.com
403-561-8989


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发